Related Experiment Videos
Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
Y S Lew1, S L Brown, R J Griffin
1Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA. younglew@yahoo.com
Abstract:
To investigate the antitumor action of arsenic trioxide in solid tumors, we carried out quantitative tumor perfusion studies, using locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice. The tumor perfusion studies were assessed by two separate methods: 99mTc clearance and 86Rb uptake. A single administration of arsenic trioxide (10 mg/kg i.p.) produced a preferential vascular shutdown in the tumor tissue at 2 and 6 h, leading to massive necrosis in the central part of the tumor. The phenomenon was repeatable at intervals of weekly administration of the drug in the same tumor. Normal skin, muscle, and kidney were relatively unaffected by arsenic trioxide. These results suggest that the drug may be investigated as an adjunct to the standard cancer therapeutic modalities.
Insights
Arsenic trioxide effectively reduces blood flow in solid tumors, causing cell death. This effect is repeatable and spares normal tissues, suggesting its potential as an adjunctive cancer therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Solid tumors often exhibit abnormal vasculature, impacting drug delivery and treatment efficacy.
- Arsenic trioxide has shown promise in certain hematological malignancies.
Purpose of the Study:
- To evaluate the antitumor effects of arsenic trioxide on solid tumors.
- To investigate the impact of arsenic trioxide on tumor perfusion and vascular function.
Main Methods:
- Quantitative tumor perfusion studies were conducted using methylcholanthrene-induced fibrosarcoma in BALB/c mice.
- Tumor perfusion was assessed via technetium-99m (99mTc) clearance and rubidium-86 (86Rb) uptake assays.
Main Results:
- A single dose of arsenic trioxide (10 mg/kg) induced significant vascular shutdown in tumor tissue within 2-6 hours.
- This vascular shutdown led to central tumor necrosis.
- The effect was reproducible with weekly administrations and did not significantly harm normal tissues (skin, muscle, kidney).
Conclusions:
- Arsenic trioxide demonstrates potent antitumor activity by targeting tumor vasculature.
- The drug's ability to induce tumor necrosis and spare normal tissues warrants further investigation.
- Arsenic trioxide may serve as a valuable adjunct to conventional cancer therapies.